Emma Martinez Sanchez’s Post

View profile for Emma Martinez Sanchez, graphic

Policy | Advocacy | Engagement | Biomedical Research | Project Management

My continuous development path is leading me these days to the field of Advanced Therapeutic Medicinal Products (ATMP) development (😍). ATMPs are a new kind of cancer treatment for both hematological and solid malignancies developed from our own immune cells (lymphocytes) and their products. I am thrilled to be learning now about this field, for two super important reasons for me, one professional and one personal: 1. I am now gaining experience in the last phase of the research cycle, bringing innovations closer to patients. In doing so I have experienced all the phases of the research cycle (knowledge chain), from fundamental exploratory research, through preclinical in live models to now closer to clinical research. I am extremely proud of this achievement and the opportunity to create along the way close collaborations / crosspolinations across disciplines to speed up healthcare innovations. 2. Having lost my own mother to breast #cancer as a young adult in 2005, it is my own personal motivation to excel in my new field to contribute to bringing therapies to patients and spare unecessary personal losses. This report commissioned by ZonMw will interest anyone in my networks working in the #atmps field. Please share widely to support the further development of this innovative therapy. 🙏 https://lnkd.in/eke8FA2m PS. I rarely dream of my mother. Yet, she visited me in my dreams last weekend. I think she is also proud of me. #atmp #livingdrugs #drugdevelopment

Geneesmiddelen voor Geavanceerde Therapie (ATMP’s) in Nederland: Veldverkenning, Knelpuntanalyse en Activiteitenkaart

Geneesmiddelen voor Geavanceerde Therapie (ATMP’s) in Nederland: Veldverkenning, Knelpuntanalyse en Activiteitenkaart

dspace.library.uu.nl

Lourens Bloem

Assistant Professor at Utrecht University | Clinical Pharmacologist in training

10mo

Inspirational motivation Emma! And thanks for sharing our report.

To view or add a comment, sign in

Explore topics